Case reports highlight improved glycemic control in type 1, type 2 diabetes, and pregnancy, suggesting effective insulin management.
Limitations in current insulin formulations contribute to suboptimal glycemic control and increased risks of hypoglycemia and hyperglycemia. Afrezza® with Technosphere® inhaled insulin (TI) offers a novel therapeutic option with a rapid pharmacokinetic and pharmacodynamic profile, addressing challenges associated with injectable insulin therapies. This article presents case reports that illustrate the clinical applications of TI across diverse patient populations, including type 1 diabetes, type 2 diabetes (T2D), pregnancy complicated by T2D, and exercise-related glycemic management.
No takes yet. Share an insight, caveat, or question.
Hirsch et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: